(Q28282846)

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Genetics of type 1A diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Immunology of beta-cell destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Autoantibodies in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

The Fourth International Serum Exchange Workshop to standardize cytoplasmic islet cell antibodies. The Immunology and Diabetes Workshops and Participating Laboratories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

A historical view from thirty eventful years of immunotherapy in autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Dietary intervention in infancy and later signs of beta-cell autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Maternal serum levels of 25-hydroxy-vitamin D during pregnancy and risk of type 1 diabetes in the offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Effects of insulin in relatives of patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Early Infant Feeding and Risk of Developing Type 1 Diabetes–Associated Autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Timing of Initial Cereal Exposure in Infancy and Risk of Islet Autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Insulin prophylaxis in individuals at high risk of type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

GAD treatment and insulin secretion in recent-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Vaccination against type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

B-cell cross-presentation of autologous antigen precipitates diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Effect of rituximab on human in vivo antibody immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Rituximab selectively suppresses specific islet antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Effect of adjuvant therapy on development of diabetes in mouse and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Effect of bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Low risk HLA-DQ and increased body mass index in newly diagnosed type 1 diabetes children in the Better Diabetes Diagnosis study in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

TEDDY--The Environmental Determinants of Diabetes in the Young: an observational clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Resuscitating adaptive Tregs with combination therapies?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.237

Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference. October 20-22, 2010, San Francisco, CA, USA.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23296174

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immune intervention studies in insulin-dependent diabetes mellitus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23296174